In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G.
We compared the activities of azithromycin, erythromycin, and penicillin G in a mouse model of systemic infection and septic arthritis induced by type IV group B streptococci (GBS). The in vitro and in vivo efficacy data for these drugs were analyzed relative to the pharmacokinetics of the drugs in sera, joints, and kidneys. Adult CD-1 mice were infected intravenously with 10(7) CFU of type IV GBS. Intraperitoneal drug administration was initiated with different dose regimens at different times after infection. A single dose of azithromycin (100 mg/kg) strongly reduced the incidence of articular lesions with respect to that with erythromycin or penicillin G. Treatment with azithromycin (three intraperitoneal administrations of 50 mg/kg at 12-h intervals) resulted in the complete prevention of arthritis. In contrast, erythromycin was poorly effective and penicillin G was effective only if inoculated 30 min after infection and at high doses (400,000 or 600,000 IU/kg). Furthermore, azithromycin was able to cure about 70% of the mice when administered 7, 8, and 9 days after GBS infection. Azithromycin was much more active than erythromycin and penicillin G with respect to bacterial killing in the joints and kidneys. In fact, cultures from these tissues were always negative no matter what treatment schedule was employed. The pharmacokinetics of azithromycin account for its superior in vivo efficacy against type IV GBS. A longer half-life and higher levels of this drug in serum and tissues with respect to those for erythromycin or penicillin G were achieved. The high affinity of azithromycin for the joints strongly supports its potential value for therapy of septic arthritis, which is a severe and frequent clinical manifestation of GBS infection.
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
L
L
Tissi
C
C
von Hunolstein
P
P
Mosci
C
C
Campanelli
F
F
Bistoni
G
G
Orefici
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001170:Arthritis, Infectious / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017963:Azithromycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002908:Chronic Disease; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D007596:Joints / Q000382:microbiology / Q000473:pathology; D007668:Kidney / Q000382:microbiology; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010400:Penicillin G / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000150:complications / Q000175:diagnosis* / Q000382:microbiology; D013292:Streptococcus agalactiae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D010406:Penicillins; D004917:Erythromycin; D017963:Azithromycin; D010400:Penicillin G